Xilio Therapeutics, Inc.XLONASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-16.3%
5Y CAGR-29.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-16.3%/yr
Annual compound
5Y CAGR
-29.2%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 19.90% |
| 2024 | -8.22% |
| 2023 | -9.85% |
| 2022 | 33.95% |
| 2021 | 133.18% |
| 2020 | 111.61% |
| 2019 | 0.00% |